MOLISAN Skin & Wound Care: documents
Copies of documents published in the source.
NCDC Laboratory Evaluation
According to NCDC documents dated 4 September 2026, the ready-to-use MOLISAN solution demonstrated full effectiveness after 15 minutes of exposure for antiseptic preparation of surgical and injection areas of the skin.
The laboratory report for MOLISAN sample 26CO414840 records No Growth for P. aeruginosa ATCC 27853, E. hirae ATCC 10541 and S. aureus ATCC 25923.
Laboratory setting: BSL-2
Official NCDC Letter
Formal conclusion / official communication
Laboratory Test Results
Underlying laboratory record supporting the letter
Archive document
Laboratory report №310-52-240
Date: 30.10.2014
Laboratory test of MOLISAN solution dated 30 October 2014. The report records physicochemical parameters; lead, arsenic and mercury were not detected.
Archive document
Declaration of conformity №01
Date: 30.10.2014 · Validity period: 30.10.2014 — 30.10.2015
Declaration of conformity for liquid MOLISAN, based on testing performed in 2014. The document card lists its validity period.
Archive document
Quality certificate GLOBALTEST №319
Date: 01.07.2015 · Validity period: 01.07.2015 — 07.2016
GLOBALTEST certificate No. 319 for MOLISAN antiseptic solution, specification No. 01-0615. The document records the product’s physicochemical parameters.
Archive document
General toxicity study — MOLISAN
Date: 2015
General-toxicity study of MOLISAN, Tbilisi State Medical University, 2015. The studied composition lists distilled water, sodium chloride and tea tree, eucalyptus and peppermint essential oils.
The 2015 preclinical study of MOLISAN found no acute toxic, cumulative, locally irritating or allergic effects of the tested preparation in laboratory animals.